Ariana Saglimbene
Family Medicine · Plainview, NYNPI 1083239024
Payments from drug & device makers
Across 108 payments — averaging $27.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$729
- Novo Nordisk$328
- Bayer$292
- Amgen$228
- Esperion Therapeutics, Inc.$221
- AbbVie$187
- plus $987 from 15 others
What the payments were for
- Food & beverage$2,971100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $729 |
| Novo Nordisk | 18 | $328 |
| Bayer | 13 | $292 |
| Amgen | 8 | $228 |
| Esperion Therapeutics, Inc. | 11 | $221 |
| AbbVie | 10 | $187 |
| Lilly USA, LLC | 4 | $167 |
| Medtronic | 1 | $163 |
| Sumitomo Pharma America, Inc. | 2 | $129 |
| DJO, LLC | 1 | $104 |
| Merck | 3 | $91 |
| Astellas Pharma US Inc | 4 | $85 |
| Kowa Pharmaceuticals America, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Mannkind Corporation | 1 | $25 |
| Phadia US Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Pfizer | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,971 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $44,368 |
| TrulicityDulaglutide | 11 | $18,765 |
| OzempicSemaglutide | 20 | $18,078 |
| EliquisApixaban | 16 | $14,519 |
| SynthroidLevothyroxine Sodium | 21 | $1,996 |
| Rosuvastatin Calcium | 56 | $847 |
| Levothyroxine Sodium | 46 | $680 |
| Metoprolol Succinate | 42 | $646 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $598 |
| Pantoprazole Sodium | 41 | $467 |
| Famotidine | 41 | $421 |
| Potassium Chloride | 12 | $358 |
| Metformin Hcl ErMetformin Hcl | 35 | $358 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $339 |
| Tizanidine Hcl | 23 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $167 | $63,13446 claims |
| Novo NordiskOzempic | $328 | $18,07820 claims |
| PfizerEliquis | $17 | $14,51916 claims |
| AbbVieSynthroid | $187 | $1,99621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Plainview
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.